This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Apr;2(4):e136-7.

doi: 10.1016/S2352-3026(15)00044-7. Epub 2015 Mar 25.

Dulanermin in indolent lymphomas: an ineffective approach

Affiliations

Affiliation

¹ Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy. Electronic address: luca.arcaini@unipv.it.

PMID: 26687955
DOI: 10.1016/S2352-3026(15)00044-7

Comment

Dulanermin in indolent lymphomas: an ineffective approach

Luca Arcaini. Lancet Haematol. 2015 Apr.

. 2015 Apr;2(4):e136-7.

doi: 10.1016/S2352-3026(15)00044-7. Epub 2015 Mar 25.

Author

Affiliation

¹ Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy. Electronic address: luca.arcaini@unipv.it.

PMID: 26687955
DOI: 10.1016/S2352-3026(15)00044-7

No abstract available

PubMed Disclaimer

Comment on

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.
Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF. Cheah CY, et al. Lancet Haematol. 2015 Apr;2(4):e166-74. doi: 10.1016/S2352-3026(15)00026-5. Epub 2015 Mar 25. Lancet Haematol. 2015. PMID: 26687959 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science